Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery.

Functional imaging methods such as fMRI have been widely used to gain greater understanding of brain circuitry abnormalities in CNS disorders and their underlying neurochemical basis. Findings suggest that: (1) drugs with known clinical efficacy have consistent effects on disease relevant brain circuitry, (2) brain activation changes at baseline or early drug effects on brain activity can predict long-term efficacy; and (3) fMRI together with pharmacological challenges could serve as experimental models of disease phenotypes and be used for screening novel drugs. Together, these observations suggest that drug related modulation of disease relevant brain circuitry may serve as a promising biomarker/method for use in drug discovery to demonstrate target engagement, differential efficacy, dose-response relationships, and prediction of clinically relevant changes.

[1]  H. Flor,et al.  Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics , 2004, Psychopharmacology.

[2]  Justin S. Feinstein,et al.  Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. , 2005, Archives of general psychiatry.

[3]  Barbara J. Sahakian,et al.  Hot and cold cognition in depression , 2013, CNS Spectrums.

[4]  G. Barker,et al.  Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology , 2012, Molecular Psychiatry.

[5]  Sylvain Houle,et al.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.

[6]  Olivier Boss,et al.  Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake , 2006, Neuron.

[7]  P. Cowen,et al.  Short-term NK1 receptor antagonism and emotional processing in healthy volunteers , 2011, Psychopharmacology.

[8]  M. Czisch,et al.  Benzodiazepines Counteract Rostral Anterior Cingulate Cortex Activation Induced by Cholecystokinin-Tetrapeptide in Humans , 2013, Biological Psychiatry.

[9]  C. Harmer,et al.  Changes in Automatic Threat Processing Precede and Predict Clinical Changes with Exposure-Based Cognitive-Behavior Therapy for Panic Disorder , 2013, Biological Psychiatry.

[10]  Axel Schäfer,et al.  Binge-Eating Disorder: Reward Sensitivity and Brain Activation to Images of Food , 2009, Biological Psychiatry.

[11]  M. Paulus,et al.  Pregabalin effects on neural response to emotional faces , 2012, Front. Hum. Neurosci..

[12]  Sergi G. Costafreda,et al.  Predictive neural biomarkers of clinical response in depression: A meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies , 2013, Neurobiology of Disease.

[13]  S. Williams,et al.  Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[14]  Piotr Bogorodzki,et al.  Cortical and limbic activation during viewing of high- versus low-calorie foods , 2003, NeuroImage.

[15]  P. Cowen,et al.  Efficacy markers in depression , 2011, Journal of psychopharmacology.

[16]  Ravi S. Menon,et al.  Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Paulus,et al.  Role of Functional Magnetic Resonance Imaging in Drug Discovery , 2007, Neuropsychology Review.

[18]  Shane McKie,et al.  Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. , 2008, Archives of general psychiatry.

[19]  Dan J Stein,et al.  Acute Effects of Sceletium tortuosum (Zembrin), a Dual 5-HT Reuptake and PDE4 Inhibitor, in the Human Amygdala and its Connection to the Hypothalamus , 2013, Neuropsychopharmacology.

[20]  John Ashburner,et al.  Multivariate decoding of brain images using ordinal regression☆ , 2013, NeuroImage.

[21]  P. Cowen,et al.  NK1 receptor antagonism and emotional processing in healthy volunteers , 2010, Journal of psychopharmacology.

[22]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[23]  Xingbao Li,et al.  Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. , 2008, Archives of general psychiatry.

[24]  Monique Ernst,et al.  fMRI predictors of treatment outcome in pediatric anxiety disorders , 2007, Psychopharmacology.

[25]  A. Simmons,et al.  Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. , 2009, The international journal of neuropsychopharmacology.

[26]  Kerry J Ressler,et al.  The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. , 2010, Clinics in laboratory medicine.

[27]  Pradeep J Nathan,et al.  Oxytocin Attenuates Amygdala Reactivity to Fear in Generalized Social Anxiety Disorder , 2010, Neuropsychopharmacology.

[28]  P. Cowen,et al.  NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. , 2009, The international journal of neuropsychopharmacology.

[29]  M. Millan,et al.  The neurobiology and control of anxious states , 2003, Progress in Neurobiology.

[30]  Xiao-Jing Wang,et al.  NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia , 2012, Proceedings of the National Academy of Sciences.

[31]  Sophie Guionnet,et al.  Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. , 2011, Journal of affective disorders.

[32]  Dean F Wong,et al.  The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development , 2009, Neuropsychopharmacology.

[33]  A. Etkin,et al.  Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. , 2007, The American journal of psychiatry.

[34]  Guy M. Goodwin,et al.  Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.

[35]  Sam R. Miller,et al.  Distinct Modulatory Effects of Satiety and Sibutramine on Brain Responses to Food Images in Humans: A Double Dissociation across Hypothalamus, Amygdala, and Ventral Striatum , 2010, The Journal of Neuroscience.

[36]  M. Angstadt,et al.  Cannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans , 2008, The Journal of Neuroscience.

[37]  Green,et al.  Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness , 1997 .

[38]  Tom Johnstone,et al.  Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. , 2009, The American journal of psychiatry.

[39]  Richard J. Davidson,et al.  A Functional Magnetic Resonance Imaging Predictor of Treatment Response to Venlafaxine in Generalized Anxiety Disorder , 2008, Biological Psychiatry.

[40]  Peter Kirsch,et al.  Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans , 2005, The Journal of Neuroscience.

[41]  David Borsook,et al.  A role for fMRI in optimizing CNS drug development , 2006, Nature Reviews Drug Discovery.

[42]  E T Bullmore,et al.  Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans , 2011, Molecular Psychiatry.

[43]  Daniella J. Furman,et al.  Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. , 2012, The American journal of psychiatry.

[44]  Mats Fredrikson,et al.  Amygdala Subregions Tied to SSRI and Placebo Response in Patients with Social Anxiety Disorder , 2012, Neuropsychopharmacology.

[45]  H. Flor,et al.  Development of alcohol-associated cues and cue-induced brain activation in alcoholics , 2002, European Psychiatry.

[46]  Konstantin Voronin,et al.  Differential Brain Activity in Alcoholics and Social Drinkers to Alcohol Cues: Relationship to Craving , 2004, Neuropsychopharmacology.

[47]  P. Cowen,et al.  Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action , 2009, British Journal of Psychiatry.

[48]  E. Bullmore,et al.  Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects , 2012, Molecular Psychiatry.

[49]  Hans-Christian Bauknecht,et al.  Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals , 2007, NeuroImage.

[50]  Robert K. Heaton,et al.  Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. , 2006, The American journal of psychiatry.

[51]  C. Beevers,et al.  Neural mechanisms of the cognitive model of depression , 2011, Nature Reviews Neuroscience.

[52]  Pia Baldinger,et al.  Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET , 2014, NeuroImage.

[53]  Pradeep J Nathan,et al.  Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist , 2012, Journal of clinical pharmacology.

[54]  A. Simmons,et al.  Escitalopram effects on insula and amygdala BOLD activation during emotional processing , 2008, Psychopharmacology.

[55]  Steven B. Lowen,et al.  Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: A bold FMRI study , 2013, NeuroImage.

[56]  J. Lorberbaum,et al.  From the Departments Of , 2022 .

[57]  M. Angstadt,et al.  Corticolimbic Brain Reactivity to Social Signals of Threat Before and After Sertraline Treatment in Generalized Social Phobia , 2013, Biological Psychiatry.

[58]  T. Furmark,et al.  Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. , 2002, Archives of general psychiatry.

[59]  J. Cryan,et al.  The age of anxiety: role of animal models of anxiolytic action in drug discovery , 2011, British journal of pharmacology.

[60]  Richard Tranter,et al.  The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. , 2009, Journal of affective disorders.

[61]  Min Zhang,et al.  Awake Rat Pharmacological Magnetic Resonance Imaging as a Translational Pharmacodynamic Biomarker: Metabotropic Glutamate 2/3 Agonist Modulation of Ketamine-Induced Blood Oxygenation Level Dependence Signals , 2011, Journal of Pharmacology and Experimental Therapeutics.

[62]  Andre F. Marquand,et al.  Test–retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers , 2013, NeuroImage.

[63]  R. Luthringer,et al.  Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge , 2010, Journal of psychopharmacology.

[64]  G. McCarthy,et al.  Relationship of Resting Brain Hyperconnectivity and Schizophrenia-like Symptoms Produced by the NMDA receptor Antagonist Ketamine in Humans , 2012, Molecular Psychiatry.